基于PIVKA-Ⅱ、AFP和AFP-L3不同组合模式的肝细胞癌筛查策略探讨

谢芳; 于乐成; 薛珠; 李平; 盛云峰

doi:10.3969/j.issn.1001-5256.2019.09.018

基于PIVKA-Ⅱ、AFP和AFP-L3不同组合模式的肝细胞癌筛查策略探讨

DOI: 10.3969/j.issn.1001-5256.2019.09.018

东部战区总医院南京中医药大学附属八一医院全军肝病中心

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1336
- HTML全文浏览量: 53
- PDF下载量: 275
- 被引次数: 0
出版历程
- 收稿日期: 2019-05-22
- 出版日期: 2019-09-20

Screening strategy for primary hepatocellular carcinoma based on different combinations of protein induced by vitamin K absence or antagonist-Ⅱ, alpha-fetoprotein, and alpha-fetoprotein-L3

Liver Disease Center of PLA, General Hospital of Eastern Theater Command & Bayi Hospital Affiliated to Nanjing University of Chinese Medicine

摘要

摘要: 目的探讨血清PIVKA-Ⅱ、AFP和AFP异质体（AFP-L3）的优化组合对肝细胞癌（HCC）筛查诊断的敏感度和特异度。方法收集2017年1月-2018年7月东部战区总医院全军肝病中心118例HCC患者和76例肝炎肝硬化住院患者的血清,分别检测PIVKA-Ⅱ、AFP和AFP-L3水平。比较各指标及其不同组合对HCC筛查的敏感度和特异度。偏态分布的计量资料2组间比较采用Mann-Whitney U检验;计数资料2组间比较采用χ2检验。分析PIVKA-Ⅱ、AFP及AFP-L3筛查HCC的效能,计算敏感度及特异度,并绘制受试者工作特征曲线（ROC曲线）。结果 HCC组PIVKA-Ⅱ、AFP水平均显著高于肝炎肝硬化组（Z值分别为7. 80、3. 80,P值均<0. 001）。HCC组中PIVKA-Ⅱ、AFP、AFP-L3阳性比例均高于肝炎肝硬化组（χ2值分别为153. 36、83. 97、168. 82,P值均<0. 001）。PIVKA-Ⅱ和AFP阳性率在HCC组差异无统计学意义（68. 6%vs 67. 8%,χ2=0. 02,P> 0. 05）,但在肝炎肝硬化组的差异有...
- 癌,肝细胞 /
- 维生素K缺乏或拮抗剂诱导的蛋白质Ⅱ /
- 甲胎蛋白类
Abstract: Objective To investigate the sensitivities and specificities of different combinations of serum protein induced by vitamin K absence or antagonist-Ⅱ ( PIVKA-Ⅱ) , alpha-fetoprotein ( AFP) , and alpha-fetoprotein-L3 ( AFP-L3) in the screening for primary hepatocellular carcinoma ( HCC) . Methods Serum samples were collected from 118 patients with HCC and 76 patients with hepatitis or liver cirrhosis who were hospitalized in Liver Disease Center of PLA, General Hospital of Eastern Theater Command, from January 2017 to July 2018, and the serum levels of PIVKA-Ⅱ, AFP, and AFP-L3 were measured. The sensitivities and specificities of each individual indicator and their different combinations in HCC screening were calculated and compared. The Mann-Whitney U test was used for comparison of continuous data with skewed distribution between groups, and the chi-square test was used for comparison of categorical data between groups. The efficiency of PIVKA-Ⅱ, AFP, and AFP-L3 in HCC screening was analyzed, their sensitivities and specificities were calculated, and receiver operating characteristic ( ROC) curves were plotted. Results The HCC group had significantly higher levels of PIVKA-Ⅱ and AFP than the hepatitis/liver cirrhosis group ( Z = 7. 80 and 3. 80, both P < 0. 001) . Compared with the hepatitis/liver cirrhosis group, the HCC group had a significantly higher proportion of patients with positive PIVKA-Ⅱ, AFP, or AFP-L3 ( χ2= 153. 36, 83. 97, and 168. 82, all P < 0. 001) . There was no significant difference between the positive rates of PIVKA-Ⅱ and AFP in the HCC group ( 68. 6% vs 67. 8%, χ2= 0. 02, P > 0. 05) , while a significant difference was observed in the hepatitis/liver cirrhosis group ( 14. 5%vs 51. 3%, χ2= 23. 37, P < 0. 001) . There was a significant difference between the positive rates of PIVKA-Ⅱ and AFP-L3 in the HCC group ( 68. 6% vs 35. 6%, χ2= 25. 83, P < 0. 001) , while no significant difference was observed in the hepatitis/liver cirrhosis group ( 14. 5% vs 9. 2%, χ2= 1. 01, P > 0. 05) . There was a significant difference between the positive rates of AFP and AFP-L3 in the HCC group ( 67. 8% vs 35. 6%, χ2= 24. 50, P < 0. 001) and the hepatitis/liver cirrhosis group ( 51. 3% vs 9. 2%, χ2= 31. 92, P < 0. 001) . In HCC screening, PIVKA-Ⅱ had a significantly larger area under the ROC curve than AFP ( 0. 832 vs 0. 662, P < 0. 01) and AFP-L3 ( 0. 832 vs 0. 656, P < 0. 01) . With PIVKA-Ⅱ > 40 mA U/ml, AFP > 10 ng/ml, and AFP-L3 > 10% as the positive cut-off values for the possibility of HCC, both PIVKA-Ⅱ and AFP had a sensitivity of 67. 8% in the ROC curve, which was significantly higher than the sensitivity of AFP-L3 ( 55%) . PIVKA-Ⅱ had a significantly higher specificity than AFP ( 85. 5% vs 48. 7%) and AFP-L3 ( 85. 5%vs 60%) . In HCC screening, positive PIVKA-Ⅱ, AFP, and AFP-L3 had a sensitivity of 29. 7% and a specificity of 98. 7%; positive PIVKA-Ⅱ and AFP had a sensitivity of 55. 9% and a specificity of 90. 8%; positive PIVKA-Ⅱ and AFP-L3 had a sensitivity of 30. 5%and a specificity of 98. 7%; positive AFP and AFP-L3 had a sensitivity of 34. 7% and a specificity of 93. 4%. Conclusion In the context of no influence from the factors including anticoagulants and cholestasis, elevated serum PIVKA-Ⅱ alone has a better value in HCC screening than elevated AFP or AFP-L3. The increase in PIVKA-Ⅱ or AFP significantly improves the sensitivity in HCC screening, and the increases in all or any two of PIVKA-Ⅱ, AFP-and AFP-L3 can significantly improve the specificity in HCC screening.
- carcinoma, hepatocellular /
- PIVKA-Ⅱ /
- alpha-fetoproteins

HTML全文

参考文献(21)

[1] TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65 (2) :87-108.

[2] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66 (2) :115-132.

[3] WANG H, LI JJ, MA HX, et al. Diagnostic value of serum AFP combined with AFP-L3 in hepatocellular carcinoma:A Meta-analysis[J]. Anhui Med J, 2016, 37 (10) :1211-1214. (in Chinese) 王浩, 李家军, 马怀幸, 等.甲胎蛋白联合甲胎蛋白异质体L3诊断原发性肝癌的Meta分析[J].安徽医学, 2016, 37 (10) :1211-1214.

[4] INAGAKI Y, TANG W, MAKUUCHI M, et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-gamma-carboxyprothrombin[J]. Liver Int, 2011, 31 (1) :22-35.

[5] SEO SI, KIM HS, KIM WJ, et al. Diagnostic value of PIVKA-Ⅱand alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21 (13) :3928-3935.

[6] JI J, WANG H, LI Y, et al. Diagnostic evaluation of Desgamma-carboxy prothrombin versusα-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China:A large-scale, multicentre study[J]. PLo S One, 2016, 11 (4) :e0153227.

[7] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017) [J]. J Clin Hepatol, 2017, 33 (8) :1419-1431. (in Chinese) 中华人民共和国国家卫生和计划生育委员会.原发性肝癌诊疗规范 (2017年版) [J].临床肝胆病杂志, 2017, 33 (8) :1419-1431.

[8] SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66 (1) :7-30.

[9] YANG JD, ROBERT LR. Hepatocellular carcinoma:A global view[J]. Nat Rev Gastroenterol Hepatol, 2010, 7 (8) :449-458.

[10] EL-SERAG HB. Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 2012, 142 (6) :1264-1273.

[11] SHU H, KANG X, GUO K. Diagnostic value of serum haptoglobin protein as hepatocellular carcinoma candidate marker complementary to afectoprotein[J]. Oncol Rep, 2010, 24 (5) :1271-1276.

[12] LEI YJ, SHI LJ, ZHAO DH, et al. FibroScan combined with serum GPC3 and AFP in early diagnosis of hepatocellular carcinoma[J]. J Clin Exp Med, 2019, 18 (9) :929-932. (in Chinese) 雷云静, 师丽娟, 赵东焕, 等.瞬时弹性成像系统联合血清GPC3和AFD在肝癌早期诊断中的价值[J].临床和实验医学杂志, 2019, 18 (9) :929-932.

[13] SVOBODOVA S, KARLIKOVA M, TOPOLCAN O, et al. PIVKA-II as a potential new biomarker for hepatocellular carcinoma–A pilot study[J]. In Vivo, 2018, 32 (6) :1551-1554.

[14] YU R, DING S, TAN W, et al. Performance of protein induced by vitamin k absence or antagonist–II (PIVKA-II) for hepatocellular carcinoma screening in Chinese population[J].Hepat Mon, 2015, 15 (7) :e28806.

[15] KIM WJ, LIM TW, PARK PJ, et al. Prognostic markers affecting the early recurrence of hepatocellular carcinoma with liver cirrhosis after curative resection[J]. Int J Biol Markers, 2019, 34 (2) :123-131.

[16] UENO M, HAYAMI S, SHIGEKAWA Y, et al. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC≤5 cm:Cohort study based on serum HCC markers[J]. J Hepatol, 2015, 63 (6) :1352-1359.

[17] PARK SJ, JANG JY, JEONG SW, et al. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma[J]. Medicine (Baltimore) , 2017, 96 (11) :e5811.

[18] HU XF, YU JP, WANG GS. The clinical value of Testing serum PIVKA-Ⅱand AFP Level for diagnosing primary hepatic carcinoma[J]. J Clin Exp Med, 2017, 16 (15) :1473-1476. (in Chinese) 胡晓菲, 於建鹏, 王钢胜. PIVKA-II和AFP在原发性肝癌中的诊断和疗效监测中的临床应用价值[J].临床和实验医学杂志, 2017, 16 (15) :1473-1476.

[19] ZHANG J, YE YB, HUANG XX, et al. The expression and application of golgi glycpprotein 73, percentage of AFP heterogeneity and total bile acid in primary hepatocellular carcinoma[J]. Labeled Immumassays&Clin Med, 2014, 22 (2) :116-118. (in Chinese) 章健, 叶迎宾, 黄秀香, 等.高尔基体糖蛋白73与甲胎蛋白异质体百分比及总胆汁酸在原发性肝癌的表达及其临床应用[J].标记免疫分析与临床, 2014, 22 (2) :116-118.

[20] MU HL, GAO JF, JIANG KT, et al. Investigation the clinical significance of alpha fetoprotein heterogeneity in the differential diagnosis of benign and malignant liver disease[J]. Chin J Trauma Disability Med, 2014, 22 (7) :26-27. (in Chinese) 慕海连, 高建飞, 姜开通, 等. AFP-L3检测在良恶性肝病鉴别诊断及肝癌预警中的临床意义[J].中国伤残医学, 2014, 22 (7) :26-27.

[21] YU R, TAN Z, XIANG X, et al. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on realworld clinical data[J]. BMC Cancer, 2017, 17 (1) :608.

施引文献

资源附件(0)

访问统计